ResMed Inc.’s (RMD) growth in the third quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its progress in digital health technology continues to drive overall revenue growth. However, a dull macroeconomic scenario and fierce competition put pressure on ResMed’s operations. In the past year, shares of this Zacks Rank #3 (Buy) company have surged 15.1%, outperforming the industry’s 8.6% growth and the S&P 500 composite’s 10.1% rise.The renowned medical device company has ...

ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America Margaret Kaczor - William Blair Davin Thillainathan - Goldman Sachs Anthony Petrone - Mizuho Group David Low - JPMorgan Saul Hadassin - Barrenjoey Dan Hurren - MST Matt Taylor - Jefferies Steve Wheen - J ...